Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Hoth Therapeutics, Inc.

Hoth Therapeutics develops innovative treatments aimed at improving patient quality of life. The company focuses on creating impactful and ground-breaking therapies.

Hoth Therapeutics

At Hoth Therapeutics, Inc.  (NASDAQ: HOTH), we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating promising drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate medications that hold immense potential to create breakthroughs and diversify treatment options.

Hoth Therapeutics, Inc

Are you registered for NobleCon? Make sure to catch our CEO, Robb Knie, as he presents at Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, College of Business, Executive Education Complex, December 3-5.
ATTENDEE REGISTRATION: https://lnkd.in/eQJf5HS8

NASDAQ:HOTH

Hoth Therapeutics

Last Close

0.90

08/11 21:00

Market Cap

4.91M

Beta: 0.12

Volume Today

70.09K

Avg: 729.84K

PE Ratio

−0.48

PFCF: −0.75

Financials Not Available